Pesquisar | BuzzingAbout

Pesquisar

Vikas Kokate @vikisheth adicionou um novo artigo in Business & Finance
2025-08-28 13:32:57 ·

Dual GIP/ GLP-1 Receptor Agonists Obesity Drugs Market Overview, Growth Analysis, Trends and Forecast By 2032

"Executive Summary Dual GIP/ GLP-1 Receptor Agonists Obesity Drugs Market: Growth Trends and Share Breakdown The global dual GIP/ GLP-1 receptor agonists obesity drugs market size was valued at USD 4.75 billion in 2024 and is expected to reach USD 17.71 billion by 2032, at a CAGR of 17.85% during the forecast period While preparing this professional and exhaustive...

0 Comentários ·0 Compartilhamentos ·37 Visualizações ·0 Anterior

Faça o login para curtir, compartilhar e comentar!
Databridge Market Research @DBMR_123 adicionou um novo artigo in Business & Finance
2025-07-16 07:03:06 ·

Lipase Inhibitors Obesity Drugs Market Evolution – From Trends to Transformation (2025–2037)

"Executive Summary Lipase Inhibitors Obesity Drugs Market : The global lipase inhibitors obesity drugs market size was valued at USD 1.21 billion in 2024 and is expected to reach USD 3.61 billion by 2032, at a CAGR of 14.68% during the forecast period This Lipase Inhibitors Obesity Drugs Market report has several aspects of marketing research and analysis which...

0 Comentários ·0 Compartilhamentos ·323 Visualizações ·0 Anterior

Faça o login para curtir, compartilhar e comentar!
Vikas Kokate @vikisheth adicionou um novo artigo in Business & Finance
2025-08-08 08:38:34 ·

Metabolic Syndrome Market Overview, Growth Analysis, Trends and Forecast By 2029

"Executive Summary Metabolic Syndrome Market Opportunities by Size and Share Data Bridge Market Research analyses a growth rate in the global metabolic syndrome market in the forecast period 2022-2029. The expected CAGR of global metabolic syndrome market is tend to be around 7.50% in the mentioned forecast period. An international Metabolic Syndrome Market report lends a hand to identify how...

0 Comentários ·0 Compartilhamentos ·182 Visualizações ·0 Anterior

Faça o login para curtir, compartilhar e comentar!